Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: Orgenesis Inc.

Market Cap 983K 849K 782K 732K 1.37M 93.42M 1.39M 9.24M 3.6M 45.47M 3.69M 3.61M 157M P/E Ratio 2023
-0.26x
P/E Ratio 2024 -0.17x
Enterprise Value 19.16M 16.55M 15.25M 14.28M 26.76M 1.82B 27.17M 180M 70.22M 887M 71.92M 70.39M 3.07B EV / Sales 2023
71.2x
EV / Sales 2024 27x
Free-Float
52.06%
Yield 2023 *
-
Yield 2024 -
Current month-16.10%
1 month+959.96%
3 months+23.75%
6 months+209.38%
Current year+230.00%
1 week 0.06
Extreme 0.06
0.5
1 month 0
Extreme 0.003
0.69
Current year 0
Extreme 0.001
0.84
1 year 0
Extreme 0.0001
1.9
3 years 0
Extreme 0.0001
15
5 years 0
Extreme 0.0001
54.9
10 years 0
Extreme 0.0001
168
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 72 02/02/2012
Chief Executive Officer 57 24/12/2013
Director of Finance/CFO 51 10/03/2026
Director TitleAgeSince
Chairman 57 14/08/2014
Director/Board Member 64 08/07/2024
Director/Board Member 47 28/10/2024
Date Insider Type Main position Quantity % Market Cap.
05/03/25Other 1,200,000 23.2142%
12/12/24Free

Director

1,875 0.0363%
12/12/24Free

Director

1,875 0.0363%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%0.00%-74.62%-96.28% 4.85M
-1.64%-3.17%-34.98%-13.43% 154B
-0.16%-1.80%-8.10%-6.47% 103B
+0.07%+2.41%-4.69%+56.67% 54.8B
+3.00%+0.30%+58.58%+48.55% 55.22B
-0.75%-3.25%-15.08%-41.85% 40.3B
-1.40%+8.93% - - 30.96B
+0.16%+3.44%-8.07%-40.16% 29.08B
-0.46%+4.55%+48.18%-8.10% 23.23B
-2.85%-3.53%-15.70%-1.83% 20.25B
Average -0.40%+0.92%-6.05%-11.43% 51.04B
Weighted average by Cap. -0.46%-0.31%-6.82%-0.05%

Financials

2023 2024
Net sales 530K 458K 422K 395K 740K 50.38M 751K 4.98M 1.94M 24.52M 1.99M 1.95M 84.9M 1.03M 894K 824K 771K 1.45M 98.38M 1.47M 9.73M 3.79M 47.88M 3.88M 3.8M 166M
Net income -55.36M -47.82M -44.06M -41.24M -77.29M -5.26B -78.49M -520M -203M -2.56B -208M -203M -8.87B -48.16M -41.6M -38.33M -35.88M -67.25M -4.58B -68.29M -453M -176M -2.23B -181M -177M -7.72B
Net Debt 21.78M 18.81M 17.34M 16.23M 30.41M 2.07B 30.89M 205M 79.82M 1.01B 81.76M 80.01M 3.49B 18.18M 15.7M 14.47M 13.54M 25.38M 1.73B 25.78M 171M 66.62M 841M 68.23M 66.78M 2.91B
Logo Orgenesis Inc.
Orgenesis Inc. is a biotech company focused on cell and gene therapies (CGTs). The Company focuses on the development of autologous therapies that can be manufactured under processes and systems that are developed for each therapy using a closed and automated approach that is validated for compliant production near the patient for treatment of the patient at the point of care. It operates in two segments: Octomera LLC (Octomera segment) and therapies related activities (Therapies segment). The Octomera segment includes mainly point of care (POCare) services. The Therapies segment includes the Company’s therapeutic development operations. The POCare Services platform is utilized by parties, such as biotech companies and hospitals for the supply of their products. Octomera’s services include adapting the process to the platform and supplying the products; adaptation of automation and closed systems to serviced therapies, and contract research organization services for clinical trials.
Employees
77
Date Price Change Volume
12/06/26 0.4950 $ 0.00% 100
11/06/26 0.4950 $ +23.75% 100
10/06/26 0.4000 $ 0.00% 1,860
09/06/26 0.4000 $ -19.19% 1,677
05/06/26 0.4950 $ +1.02% 135
  1. Stock Market
  2. Stocks
  3. ORGS Stock
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!